Showing results (261-270 of 324) with videos related to
Sort By:
Pageof 33
The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2017
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung CancerJames Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, et al.The Lancet. Respiratory Medicine|October 24, 2017
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion studyMyung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, et al.The Lancet. Oncology|October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyCorey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 StudyCharles M Rudin, Mark M Awad, Alejandro Navarro, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung CancerHossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.JTO Clinical and Research Reports|November 13, 2023
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLCHye Ryun Kim, Mark M Awad, Alejandro Navarro, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2011
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancerEng-Huat Tan, Glenwood D Goss, Ravi Salgia, et al.JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJames Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.The New England Journal of Medicine|October 17, 2025
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.Pageof 33